ERBB2 and breast carcinoma: For instance, HER2-targeting CAR-T cell therapy has exhibited potent cytotoxicity toward HER2-positive breast cancer cells in preclinical studies, thereby providing a novel therapeutic strategy for patients with this subtype (8).